Category: Market News

Transense Technologies (LSE:TRT), the AIM-listed developer of advanced sensing and measurement technologies, has indicated that trading for the year ended 30 June 2026 will come in slightly below previous expectations as delays in contract progression and softer demand within its Translogik division affected short-term performance.

The company expects to report revenue of at least £4.6 million, adjusted EBITDA of no less than £0.5 million and an adjusted pre-tax result close to break-even. The revised outlook reflects lower-than-anticipated sales of Translogik products to major global tyre manufacturers, as well as slower customer commitments relating to engineering and development costs.

SAWsense Growth Offsets Areas of Weakness

Despite the near-term headwinds, management highlighted continued progress across its SAWsense business, which has delivered increasing revenues and a strengthening commercial pipeline. The company also reported stable royalty income from Bridgestone’s iTrack tyre monitoring system, which continues to provide a recurring revenue stream.

While several larger commercial opportunities have taken longer to convert than originally expected, Transense said it remains encouraged by ongoing customer engagement and the quality of its pipeline. As a result, expectations for FY27 have been moderated, although management believes the business retains positive operational momentum.

Medium-Term Confidence Remains Intact

The board stated that it remains confident in the company’s medium-term growth prospects as it works towards securing a number of significant contracts currently under discussion. Management believes the combination of expanding SAWsense adoption, recurring royalty income and future contract wins positions the business well for longer-term development.

From an investment perspective, Transense continues to benefit from solid financial fundamentals, including revenue growth, strong gross margins, improving free cash flow generation and minimal leverage. However, these strengths are currently offset by weak technical indicators, with the share price trading well below key moving averages and momentum measures such as RSI and Stochastic indicators remaining at depressed levels. Valuation remains moderately supportive, with the shares trading on a price-to-earnings ratio of approximately 12.16.

More about Transense Technologies

Transense Technologies PLC is a UK-based developer of advanced sensing and measurement solutions serving customers across aerospace, automotive, industrial machinery and commercial vehicle markets. The company operates through its SAWsense and Translogik divisions and also receives royalty income from Bridgestone’s iTrack tyre monitoring platform.

SAWsense specialises in Surface Acoustic Wave sensor technology for mission-critical applications, while Translogik supplies intelligent tyre inspection and management equipment used by leading tyre manufacturers and fleet operators worldwide. Through these complementary businesses, Transense provides data-driven monitoring solutions designed to improve safety, efficiency and operational performance.

ValiRx plc (LSE:VAL) has reported its audited results for 2025, outlining the completion of a strategic review that has narrowed the company’s focus to three key priorities while repositioning its Inaphaea BioLabs division to primarily support internal development programmes alongside selected external partnerships. The company also benefited from non-dilutive R&D tax credits and continues to utilise its patient-derived cell (PDC) biobank and collaborative network to advance future pipeline opportunities.

Cost Reduction and Portfolio Rationalisation

During the year, ValiRx reduced administrative expenses by more than £300,000 through board and workforce restructuring measures. The company also exited several evaluation and licensing arrangements that were considered outside its strategic focus, while entering new evaluation agreements with organisations including Altus Healthcare and McGill University as part of a more selective commercial approach.

The group also terminated its TheoremRx agreement, established Blue Ribbon Bio to progress the VAL201 programme, and licensed VAL401 to Ambrose Healthcare in return for an equity interest. In addition, ValiRx expanded its capabilities in AI-driven biomarker discovery and in-silico clinical trials through partnerships with Cellomatics Biosciences and TwinEdge Bioscience.

Financial Performance and Going-Concern Considerations

ValiRx recorded a total comprehensive loss of £2.23 million for the year, reflecting substantial goodwill impairments related to VAL401 and VAL201. Excluding these non-cash charges, the company reported an improvement in its underlying loss position.

Cash resources declined to £0.79 million at the end of 2025, leading management to implement further measures after the reporting period to conserve capital. These actions included voluntary salary reductions and changes to the company’s advisory board structure. Auditors also identified a material uncertainty relating to going concern, citing the group’s dependence on future fundraising activity to support ongoing operations.

Strategic Outlook

Management believes the completion of its strategic and operational restructuring has left the business better positioned to navigate the challenging funding environment facing early-stage biotechnology companies. The company is now operating with a leaner cost base and a more selective framework for assessing new opportunities.

ValiRx intends to focus on advancing higher-quality later-stage assets, extracting greater value from the Inaphaea biobank platform, and expanding targeted academic and commercial collaborations. The company believes this approach could improve its ability to secure partnership agreements, attract non-dilutive funding and generate long-term value for shareholders.

From an investment perspective, ValiRx continues to face pressure from ongoing losses and its reliance on external financing. Technical indicators point to a generally bearish trend, although some scope for short-term upside remains. Valuation metrics are also challenged by a negative price-to-earnings ratio and the absence of a dividend yield.

More about ValiRx

ValiRx plc is a UK-based life sciences company focused on developing early-stage therapies in oncology and women’s health. The business uses its translational research expertise to advance novel drug candidates from pre-clinical development towards clinical readiness and commercial partnering opportunities.

Through its Inaphaea BioLabs division, which operates a patient-derived cell biobank, and a broad network of academic and industry collaborators, the company aims to reduce development risk and accelerate asset progression. ValiRx typically advances programmes to a value-inflection point before seeking outlicensing or further development through dedicated subsidiary structures and strategic partners.

GEO Exploration Limited (LSE:GEO) has reported positive initial field results from its Gorge Project in Western Australia, where visible and coarse gold has been observed in quartz vein samples at the Gorge Mine, 401 and Central Zone prospects. Geological mapping and structural measurements indicate favourable conditions for orogenic gold mineralisation, supported by extensive historic hard-rock workings and well-exposed metasedimentary rocks.

The company has collected 35 rock chip samples and 246 orientation soil samples across key target areas, with soils submitted for laboratory analysis to shape a broader geochemistry campaign. Identification of copper-rich gossan and evidence of historic production of lead and silver underscore the project’s multi-commodity potential, while confirmed access, water sources and historic drill collar locations strengthen the groundwork for future systematic follow-up work and potential drilling, subject to approvals.

More about GEO Exploration Limited

GEO Exploration Limited is a mineral exploration company listed on London’s AIM market, focused on gold and multi-commodity projects in Western Australia. The company targets orogenic gold systems and associated base metals such as copper, lead and silver, advancing early-stage assets through systematic fieldwork and geochemical programmes.

Proteome Sciences plc (LSE:PRM) has announced the award of a major new clinical contract tied to its target engagement and chemoproteomics platform, marking another milestone ahead of an anticipated clinical trial programme expected to begin later in 2026. The company said the agreement reflects growing traction for its chemoproteomics offering and follows strong industry engagement at the American Society for Mass Spectrometry conference in San Diego, highlighting increasing demand for its specialist proteomics expertise.

The contract is expected to strengthen Proteome Sciences’ revenue opportunities while expanding its involvement in clients’ clinical development activities. As programmes advance, the company could benefit from additional follow-on work, reinforcing its position within the contract proteomics sector. Greater exposure among drug development and mass spectrometry professionals may also support future growth in higher-value chemoproteomics projects.

Outlook and Key Considerations

Despite positive commercial momentum, Proteome Sciences continues to face financial challenges. The company has been impacted by lower revenues, negative gross margins, ongoing losses and a balance sheet under pressure from increasing debt levels and significantly negative equity.

From a market perspective, technical indicators provide only limited support. While the shares have experienced a short-term recovery, they remain below the 200-day moving average and the MACD indicator remains negative. Valuation metrics are also constrained by continuing losses, resulting in a negative price-to-earnings ratio, while dividend data remains unavailable.

More about Proteome Sciences

Proteome Sciences plc specialises in contract proteomics services designed to support drug discovery, clinical development and biomarker research. The company uses proprietary technologies to analyse tissues, cells and biological fluids, helping researchers identify disease biomarkers and better understand therapeutic targets.

Its technology portfolio includes SysQuant, TMT MS2 and chemoproteomics platforms such as Solvent Shift and TMTcalibrator, which provide high-sensitivity target identification, mechanism-of-action analysis and biomarker discovery across a broad range of plasma proteins.

The company also develops targeted mass spectrometry assays that deliver highly accurate biomarker measurements in situations where conventional immunoassays are not available. Through the combination of protein depletion techniques and extensive proteome coverage, Proteome Sciences aims to provide pharmaceutical and biotechnology companies with advanced analytical capabilities for clinical and translational research programmes.

Central Banks Shift Focus Back to Inflation

Barclays believes a growing number of major central banks are becoming more focused on controlling inflation, a development that could reduce one of the key drivers behind the strong performance of global equity markets in recent years.

The change comes after a series of policy decisions from leading central banks, many of which cited inflation risks linked to higher energy costs following the Iran conflict and disruptions to shipping through the Strait of Hormuz.

The European Central Bank delivered its first interest-rate increase since 2023, while the Bank of Japan raised borrowing costs to their highest level since 1995. Both institutions pointed to concerns that energy-related price pressures could spread across broader areas of the economy.

Federal Reserve Adopts a Firmer Tone

Although the Federal Reserve left interest rates unchanged this week, policymakers signalled a more hawkish stance than markets had expected.

Nine Fed officials now anticipate at least one additional rate increase before year-end, compared with none in the central bank’s March projections. Investors also focused on the wording of the Fed’s latest statement under Chair Kevin Warsh, which emphasised the goal of achieving “price stability” while omitting references to maximum employment.

The Bank of England also kept rates on hold, but Barclays noted that the voting split continued to reflect a hawkish bias despite softer inflation and labour market data.

Liquidity Could Become a Headwind for Stocks

Barclays strategist Emmanuel Cau and his team said recent developments represent “a clear shift in the global monetary policy backdrop.”

They argued: “After a prolonged period of synchronized rate cuts across the Western world, the tailwind from monetary policy easing is behind us. At the same time, uncertainty around the reaction function of central banks, particularly the balance between growth and inflation risks, may contribute to higher bond market volatility.”

The analysts cautioned that a more aggressive Federal Reserve could eventually begin to undermine one of the main supports for equity markets.

According to Barclays, if the Fed were to move “more decisively” toward fighting inflation and enter another tightening cycle, “it would start to squeeze liquidity and weaken a key pillar of support that has underpinned bullish equity market returns over the past two years.”

While the bank stressed that this is not its “base case,” it remains “a risk to monitor.”

U.S.-Iran Agreement Offers Some Relief

Despite concerns over monetary policy, Barclays highlighted the positive impact of the interim peace agreement between the United States and Iran.

The analysts described the deal as “a welcome relief” for investors, noting that lower geopolitical risks have contributed to falling oil prices and eased some inflation concerns.

Markets are now closely watching the reopening of the Strait of Hormuz, through which around one-fifth of global oil and liquefied natural gas shipments passed before the conflict. Although shipping activity has started to recover, some strategists believe it could take time before traffic returns to pre-war levels.

Europe May Be Positioned to Benefit

Barclays sees improving opportunities in Europe as macroeconomic conditions potentially strengthen during the second half of the year.

The analysts said: “From a regional perspective, the potentially better macro outlook for [the second half] should be supportive of [year-to-date] laggards such as Europe, leading us [to] close our underweight on the region, particularly with positioning still skewed toward a tech/semis-heavy United States.”

They also highlighted potential opportunities within consumer-focused sectors. “At the sector level, as lower oil prices boost consumer confidence from the lows, the risk-reward for some consumer cyclicals, most notably for luxury, should improve even after their recent short squeeze led bounce,” the Barclays analysts said.

JPMorgan believes the semiconductor sector is becoming increasingly vulnerable to bouts of sharp volatility as investor positioning reaches elevated levels and valuations continue to stretch.

In a research note on Thursday, analyst Nikolaos Panigirtzoglou warned that rising volatility combined with concentrated exposure is “raising the risk of more frequent semiconductor ‘VaR shocks’ from here,” pointing to the early-June selloff as an example of how quickly market conditions can deteriorate.

The bank identified concentration as one of the biggest risks facing the sector. As semiconductor stocks occupy a larger share of global equity indices, Panigirtzoglou said their weight “can become binding for funds with self-imposed risk limits,” potentially triggering forced reductions in exposure during periods of stress.

Valuation is another area of concern. JPMorgan noted that semiconductor companies now command a market-capitalization-to-revenue ratio within global indices that exceeds six times, a level significantly higher than that of the Magnificent Seven stocks in the S&P 500 when Broadcom is substituted for Tesla.

The bank also highlighted a potential catalyst for volatility in the near term. End-of-quarter and end-of-month portfolio adjustments could result in roughly $165 billion flowing out of equities and into bonds, creating additional pressure on sectors that have become heavily owned by investors.

Outside equities, JPMorgan pointed to growing risks in digital assets. The bank observed that bitcoin mining profitability has become increasingly dependent on cryptocurrency prices, suggesting that a larger share of miners are operating close to break-even levels.

JPMorgan concluded that while concentration has historically supported momentum during powerful rallies, the semiconductor sector’s current combination of rich valuations, crowded positioning and elevated volatility leaves it increasingly exposed to sharper market swings.

The International Energy Agency has downgraded its forecast for global oil demand in 2026, pointing to prolonged supply disruptions in the Gulf region, while expecting conditions to improve steadily over the following year.

The agency now forecasts a decline of 1.1 million barrels per day in global oil demand next year, compared with its previous estimate for a reduction of 420,000 barrels per day. Higher energy costs and ongoing supply constraints were cited as the primary drivers behind the revision.

Demand is expected to recover in 2027, with the IEA projecting growth of 2 million barrels per day as trade routes reopen, supply chains stabilize and economic activity strengthens.

Diplomatic Progress Offers Hope for Energy Markets

The agency highlighted the preliminary agreement reached between Washington and Tehran as a major development in efforts to resolve the conflict.

A formal signing is expected later this week, and the IEA described the agreement as the most significant diplomatic breakthrough since hostilities began.

“While details of the deal have yet to be clarified and several issues remain outstanding, it is an encouraging step forward,” the IEA said. “A full recovery will not be immediate, however, as mines will have to be removed from the main shipping lanes and supply chains will take time to normalise.”

Crude Prices Extend Weekly Losses

Oil prices continued to retreat as traders responded to improving geopolitical sentiment.

Brent crude slipped below $80 per barrel, while WTI traded around $76. Brent has now fallen more than 8% this week and is trading at levels not seen since early March.

The decline reflects growing expectations that global energy supplies will gradually recover if the agreement proceeds as planned.

Supply Recovery Expected Next Year

The IEA forecasts global oil supply will fall by 3.9 million barrels per day in 2026, largely because significant volumes remain stranded in the Persian Gulf.

Roughly one-fifth of the world’s oil supply continues to be affected by the disruption, although the agency expects a substantial rebound next year as exports and shipping activity resume.

Production in May remained 13.6 million barrels per day below pre-conflict levels, while exports from Gulf producers were down 1.1 million barrels per day and almost 15 million barrels per day below February levels.

Inventory Drawdowns Highlight Market Tightness

Global oil stockpiles continued to shrink during May, declining by 143 million barrels.

Since the conflict began, inventories have been falling at an average rate of 3.8 million barrels per day, underscoring the pressure on available supplies.

Meanwhile, OECD government inventories fell by 163 million barrels, reaching their lowest level in more than three decades.

Despite signs of diplomatic progress, the agency indicated that rebuilding supply chains and restoring market balance will remain a gradual process.

The dominance of artificial intelligence stocks in global equity markets is drawing comparisons with the late stages of the dot-com boom, although KB Securities believes the trend may indicate continued strength rather than an imminent reversal.

Analyst Euntaek Lee said in a research note that current market conditions are “largely the same” as those witnessed in 1999, when investors overwhelmingly favored internet-related companies and largely ignored sectors with strong underlying earnings performance.

Lee pointed out that healthcare and financial stocks enjoyed robust earnings-driven gains in 2025 but “have been left out of the rally simply because they are not AI plays.”

The analyst also highlighted similarities in investor sentiment. During the dot-com bubble, stocks frequently rallied on announcements linked to internet strategies, regardless of their earnings prospects.

According to Lee, today’s AI market is exhibiting comparable behavior, with shares “skyrocketing on news of a visit by Jensen Huang, or a hint of forays into AI/robotics, despite the absence of related earnings.”

Rather than viewing the narrowing leadership as a clear signal of market exhaustion, Lee argued that concentration can often accompany the strongest phases of a bull market.

“History shows that, in many cases, rising concentration indicates that the market still has momentum,” he wrote.

Even so, the analyst cautioned that excessive concentration can eventually create vulnerabilities. He noted that “rally broadening is not necessarily healthy” and “may be a sign that the rally is approaching its end.”

For now, KB Securities expects leadership within equity markets to become even more concentrated, following a pattern commonly observed during the final stages of previous speculative booms.